Medical Advices

If you're new here, you may want to subscribe to my RSS feed. Thanks for visiting!

Zenerx is a natural herbal classic supplement.In the composition is having also nitric oxide and for that the producers are stating that can really produce a very strong erection. This formula include: Garlic Bulb Extract to help activate nitric oxide in the body and increase blood flow; Cnidium Monnieri, used to boost libido in Chinese medicine; Magnolia Bark Extract, used to ease tension and Cordyceps Extracts, a mushroom that may be helpful for immune function and also Niacin, which help to dilate blood vessels and Zinc to increase potency.
Anathor popular supplement on the market is Paravol . According to the producers websites ” Paravol stimulates the body’s natural production of testosterone”. Paravol formula contain: Muira Puama Herb, Tribulus Terrestris, Maca, Catuaba Bark Extract Avena Sativa, Long Jack,Sarsaparilla , Stinging Nettle and Horney Goat Weed.You have to “buildup” a period as the producer advertise.For some consumers this supplement worked.
Another herbal supplement is Ezerex .The producers advertise this prodaluct that will overcome pre-ejaculation also. The feedback about this product is not very positive, many customer complain about this product. This supplement contains:
Horny Goat weed, Korean Ginseng, Ginger Root, Yohimbe, Bombyx Mori,Cordyceps, Schizandra Berry, Rehamannia Root. On the product website it is specified a money back guarantee.

WALTHAM, Mass., Aug. 21 /PRNewswire/ — Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that opportunities abound to improve the market prospects for drugs and reverse the pharmaceutical industry’s decade-long productivity and performance slide. With pharmacogenomics technology and personalized medicine development, pharma companies can produce a new generation of targeted therapies that impact their bottom line.
Drugs such as Genentech/Roche’s Herceptin and Novartis’s Gleevec have demonstrated the success of targeted therapies from both a scientific and a business standpoint. Both drugs are mega-blockbusters; in 2007, sales of Herceptin totaled $4.05 billion and sales of Gleevec, $3.05 billion. Despite these early successes, the development of targeted medicines and the translation of pharmacogenomics-based testing into medical practice have been slower than anticipated, and the promise of personalized medicine is still largely to be realized.
“The secret to getting ahead with pharmacogenomics-based drug development comes from a new mindset in the pharmaceutical industry,” said Lulu Pickering, Ph.D., analyst in the Spectrum executive advisory service at Decision Resources. “Nichebusters also make good business sense, and a good return on investment can indeed be obtained from value-added drugs.”
The new Decision Resources Personalized medicine Series suggests that personalized medicine not only has the potential for good: directing the right drug to the right patient to enhance therapeutic outcome and to prevent some patients from being harmed by drug treatment, but it also has the potential for harm: upsetting the way pharmaceutical companies have long done business and tampering with the industry’s sacred cow-the blockbuster model of drug development.
“The blockbuster model of drug development is, of course, still relevant to the pharmaceutical industry,” stated Dr. Pickering. “At the same time, however, companies must adopt technologies and new business strategies that will enable them to develop better drugs-value-added drugs-that can command the prices capable of providing an acceptable return on investment for the companies that develop them.”
About Decision Resources’ Spectrum Personalized medicine Series
Is the traditional blockbuster model still viable? Although no clear answer has emerged, a new paradigm-personalized medicine-has been proposed. Personalized medicine requires finding the right medicine for the right person at the right time, and represents a major shift in medical approaches and business models across therapeutic areas. Decision Resources’ Spectrum Personalized medicine Series explores key trends, drug and diagnostic technologies, players and strategies and provides strategic insight that will help you successfully navigate this paradigm shift. It explores more about diet pills as well, although you could go to diet pills hut to learn more about it.
The Spectrum Personalized medicine Series 2008 titles include:

– How to Get Ahead with Pharmacogenomics
– How to Integrate Personalized medicine into Business Strategies
– Enabling the Path to Personalized Medicine
– Licensing Strategies in the Age of Personalized Medicine
– Biomarker Opportunities for Novel Targeted Cancer Therapies
– Blood Biomarkers and Beyond: Biomarker and Diagnostic Opportunities in
Cardiovascular Disease
– Emerging Diagnostic Technologies for Use in Psychiatric Indications
– The Landscape of Companion Diagnostics: Challenges, Opportunities, and
Future Trends

About Decision Resources

Decision Resources () is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:

Elizabeth Marshall
Decision Resources
781-296-2563

Decision Resources

LONGVIEW, Texas, July 22 /PRNewswire/ — Consumers who are searching for the best deals in health & beauty products now have a new online resource: RxPop.com (), a division of Rxium, LLC. Known for its award-winning website, which features prescription drug price comparisons and online pharmacy referrals, RxPop.com has just teamed up with the undisputed heavyweight champion of price comparison shopping to provide a reputable consumer resource for researching health & beauty products, as well as comparing the costs of everything from makeup brushes, popular cosmetics and personal care items to health monitors, nutritional supplements, fitness equipment and more. RxPop’s Home health Search has officially opened its online doors at
“This is really big news for RxPop,” says William Hill, CEO of Rxium LLC and founder of RxPop.com. “Basically, we’ve signed an exclusive deal with the giant of online price comparisons where we’re able to promote and access their health & beauty store while continuing to provide our pharmacy referrals and prescription price comparisons. This has resulted in an online superstore dedicated to these complementary industries but under the RxPop umbrella. It’s a natural partnership — the two companies go hand in hand.”
RxPop’s newest partner was acquired by Experian in 2005 for $485 million and is the largest price-comparison website to date. In addition to health & beauty, it provides price comparisons for a wide selection of small- and big- ticket goods, ranging from flowers to appliances and furniture. RxPop.com’s latest affiliation is yet another example of how this online interactive application carefully picks its business alliances, partnering with only the elite, Hill says.
“RxPop.com has quickly gained the respect and recognition from several Internet giants,” Hill says. “This first led to a partnership with Healthcare.com of Miami and now our newest friends headquartered in Los Angeles with office locations in eight different countries around the globe. Our collective efforts are providing bigger and better services to consumers, which is RxPop’s primary goal.”
While RxPop’s latest partner has expressed interest in the possibility of powering its prescription drug price comparisons, RxPop.com will continue building on its current platform for now. Home health Search will be set up in accordance with RxPop.com’s signature brand. This approach will help ensure solid conversions and impressive returns while providing the user an interactive experience in the form of a service.
About RxPop.com
RxPop.com, a division of Rxium LLC, is the leading online destination for consumers searching for prescription drug price comparison and licensed online pharmacy referral services. Led by a talented team of e-commerce experts, the award-winning RxPop.com offers price comparisons on over 13,000 medications being sold by approximately 50 of the Internet’s largest and most reputable pharmacies. All of RxPop.com’s participating pharmacies are legitimate companies, and licensed in their governing countries, including the United States and Canada. RxPop.com is the most secure and convenient way for consumers to search and perform up-to-date price comparisons for prescription drugs online.
For more information on RxPop.com, a division of Rxium LLC, visit or contact us directly at press @ rxpop.com
Contact:
Rxium LLC
press @ rxpop.com

SOURCE: Rxium LLC
RxPop.com is a division of Rxium LLC

This release was issued through eReleases(TM). For more information, visit .
Rxium LLC

HOUSTON, Aug. 12 /PRNewswire-FirstCall/ — Bederra Corporation (Pink Sheets: BDRR), a medical imaging and diagnostic company, announced today that its wholly-owned subsidiary Lumar Imaging, Inc. has entered into a Joint Venture (JV) agreement with Advanced Nuclear Consultants, LLC, a leading provider of refurbished nuclear gamma cameras with state-of-the-art technology. According to the JV, Lumar’s facility will offer nuclear imaging services in the areas such as Cardiac, Bone, Brain, Thyroid, Gastrointestinal and a variety of other specialized Imaging tests.
The non-invasive nature of nuclear medicine imaging systems makes it favorable for physicians and patients alike, and demand for nuclear medicine is dramatically on the rise. The North American Nuclear medicine Market earned revenues of over $18 billion in 2007 and is bound to reach $20 billion in 2014, according to estimates by Frost & Sullivan.
“Since diagnostic imaging is the precursor to nuclear imaging, our JV with Advanced Nuclear is ideal for extending the doctor referral network,” said Graham Williams, CEO of Bederra Corporation. “Combined with our recent JV with Basic Solutions, Inc., Lumar is creating a synergistic platform to cost-effectively create new sales opportunities to drive shareholder value. We anticipate this JV will bring an additional $1 Million to Lumar’s annual revenues.”
Advanced Nuclear Consultants, LLC is based in Houston, Texas and provides national sales, service and technical support for nuclear imaging systems. The company specializes in nuclear medicine consulting for private practice, diagnostic imaging centers and hospitals. For more information, visit .
“Our joint venture is a monumental occasion for us and we are all excited about the long-term opportunities to better serve our community with exceptional levels of health care services through Lumar Imaging, Inc.,” said Richard Armijo, president of Advanced Nuclear Consultants, LLC.
Lumar Imaging is a six-year old facility that provides MRI, CT, Ultrasound and Pain Management services to the greater Houston area and is located adjacent to the world famous Texas Medical Center.
About Bederra Corporation
Bederra Corporation, through its wholly owned subsidiaries Diagnos, Inc. and Lumar Imaging, Inc., provides multiple modality diagnostic medical imaging services to the greater Houston area and the world famous Texas Medical Center. The Company’s business strategy is to continue to expand its current operations and seek out additional acquisitions that will complement its core offerings.
Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products and services in development, including any planned acquisitions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements may not occur. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company’s plans or expectations.
Bederra Corporation

ROCKVILLE, Md., July 2 /PRNewswire-FirstCall/ — InforMedix Holdings, Inc. (BULLETIN BOARD: IFMX) is pleased to announce that Auburn University’s Harrison School of Pharmacy has successfully incorporated InforMedix’s Med-eMonitor and Med-eXpert Systems into its teaching curriculum, to teach the role of the community pharmacist in ensuring proper medication adherence and holistic health management and consulting. Acting as a “community pharmacist,” a team of pharmacy students and their advisors evaluated pharmacy early practice experience patients for potential benefit from the Med-eMonitor smart pillbox and Med-eXpert information system, which provides real-time, customizable, actionable information on the medication adherence and health status of chronically ill patients. They selected a woman taking 14 different medications, who is taking these medications to treat congestive heart failure, high blood pressure, osteoporosis, chronic pain, and to reduce her risk of stroke. In addition to monitoring the adherence for each of the 14 medications, the patient is being monitored for general health status, and for any changes to her prescribed medication regimen. Benefitting from the urgent alerts being sent from Med-eXpert to the student pharmacist and family members who worked together to ensure that the patient remained adherent to her medication and that her health remained stable, the patient also took her Med-eMonitor with her on vacation to maintain these benefits while away.
The Med-eMonitor and Med-eXpert Systems received strongly positive reviews from the patient, her family members, and pharmacy faculty members at Auburn’s Harrison School of Pharmacy. Auburn University has an international reputation for evaluating and teaching how cutting edge technology can enhance the practice of pharmacy, and the role of the pharmacist as a consultant in holistically evaluating and advising patients with respect to their medications and health.
Bill G. Felkey, Professor of Pharmacy at Auburn University, commented, “For some time now I have incorporated the Med-eMonitor and Med-eXpert Systems into my presentations on cutting edge tools to be used by pharmacists to enhance their consulting capabilities and professional identity. It is truly a closed-loop solution that has stood the test of time. The next step was to actually deploy InforMedix’s medication adherence and health status information solutions live in our teaching environment to provide hands-on, real-time experience for our pharmacy students. I am pleased to report that we have been highly satisfied with both the Med-eMonitor smart pillbox and Med-eXpert Information System in linking together the patient, family members, and pharmacist to optimize her health and medication adherence, and provide an important and central role for the pharmacist. Med-eXpert’s real-time alerts have provided valuable information to enable the pharmacist to provide targeted interventions to improve the patient’s medication adherence and health status.”
Bruce A. Kehr, M.D., CEO of InforMedix, noted, “We are privileged that the internationally renowned Harrison School of Pharmacy at Auburn University selected our Med-eMonitor and Med-eXpert Systems as part of their teaching curriculum, and that their levels of satisfaction were high. This supports an important commercial role for our Med-ePhone, Med-eMonitor, and Med-eXpert information solutions in independent and chain drug stores, to enhance the practice of pharmacy, and enable pharmacists to more effectively support the medication adherence and health status of their consumers.”
About InforMedix
InforMedix provides its patented Med-eXpert(TM) information system providing real-time, customizable and actionable information on the medication adherence and health status of chronically ill outpatients.
Two portable appliances are used by patients to follow their medication and care plans, and to record and transmit medication adherence and health status information to the Med-eXpert System. The Med-eMonitor(TM), a portable, interactive, “smart pillbox,” which stores and/or manages up to 25 medications, while tracking patients’ adherence to their medications and care plans, and The Med-ePhone(TM), which prompts, monitors and records medication adherence and health status assessment delivered to patients over mobile phones and landlines using Interactive Voice Response Systems (IVRS). Mission-critical information can be uniquely customized for each customer’s and patient’s needs at both individual and population levels to more effectively and efficiently reduce healthcare costs, improve health outcomes and increase patient satisfaction. InforMedix Solutions consistently achieve medication and care plan adherence rates of 90% or more across multiple chronic disease populations, as documented by academic medical center trials and peer-reviewed journal articles. For more information, visit .
About Auburn University’s Harrison School of Pharmacy
The James I Harrison School of Pharmacy is proud to be a part of the Auburn University family. Situated in east central Alabama, Auburn University is not only the largest university in the state of Alabama, but is consistently the highest ranked university according to U.S. News and World Report. For the 2002-2003 academic year, the magazine ranked Auburn 43rd among the nation’s top public universities. This is the 10th consecutive year that Auburn has been ranked among the nation’s finest public universities.
Safe Harbor Statement
This press release may contain forward looking statements that involve risks and uncertainties, including statements regarding our business strategy and development plans, plans for entering into new businesses, anticipated sources and uses of funds and other statements regarding our plans, objectives, expectations and intentions that are not historical facts. Because these forward-looking statements involve risks and uncertainties, actual results could differ materially from those discussed in this press release. These risks and uncertainties are described in greater detail in the reports that we file with the Securities and Exchange Commission. Our actual results, performance or achievements may vary materially from those expressed or implied in any forward-looking statements. All forward-looking statements reflect our beliefs and expectations as of the date of this press release and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise.
InforMedix Holdings, Inc.

CEDAR KNOLLS, N.J., June 18 /PRNewswire-FirstCall/ — MedeFile International, Inc. (BULLETIN BOARD: MDFI) , a company specializing in portable electronic medical records management solutions, today announced that in collaboration with the Newark Fraternal Order of Police (NFOP), Lodge #12, the Company will supply every NFOP member police officer with MedeFile Basic memberships, which may then be upgraded to MedeFile Premium memberships by each officer at his or her own election.
Derick Hatcher, President of the NFOP, stated, “Law enforcement is a very dangerous business, requiring police officers to place their lives at risk every single day. In the event of a medical emergency involving an officer - particularly one in which he or she may be unconscious or otherwise unable to communicate, having immediate access to critical medical insight about the officer could prove to be vital. Teaming with MedeFile will ensure that our member officers are never without their personal emergency medical information.”
Law enforcement has become an area of focused marketing by MedeFile over the past several months. “It is MedeFile’s opinion that having immediate access to personal medical records is just as important as carrying a firearm when it comes to providing enhanced security and protection for an officer. Consequently, our sales and marketing teams have been actively engaged in discussions and marketing initiatives targeting our nation’s law enforcement agencies, and our message is beginning to resonate throughout the country,” stated Milton Hauser. “In addition to winning the enthusiastic support of the Newark Fraternal Order of Police, MedeFile enrolled nearly 1,000 new members - officers from all across the country - into the MedeFile system during our recent participation in National Police Week in Washington, D.C.”
MedeFile International’s overriding mission is to revolutionize the healthcare industry and empower patients by providing a ‘one-stop-shop’ secure solution for acquisition, organization and management of all actual medical, dental and general health records and images, regardless of their origin or nature. Moreover, the Company is committed to providing everyone within the universal healthcare system with efficient, secure, simple and cost-effective tools and services to facilitate the best, most economical, application of medical and health information, thus helping to enhance patients’ medical outcomes without unnecessary costs, unnecessary redundancy in testing and treatment protocols, and unnecessary hassle typically associated with managing unwieldy ‘paper’ records and files.
By subscribing to MedeFile, not only will members empower themselves to take control of their own health and well-being, they empower all healthcare providers to make sound and lifesaving decisions with the most accurate, up-to-date medical information available. In addition, with MedeFile, members enjoy the peace of mind that comes from knowing that family medical records are protected from fire, natural disaster, document misplacement or the closing of a medical or dental practice.
About MedeFile International, Inc.
MedeFile has developed a proprietary system for gathering and digitizing medical records so that individuals can have access to a comprehensive set of their medical records. MedeFile’s primary product is the MedeFile system, a highly secure system for gathering and maintaining medical records. The MedeFile system is designed to gather all of its members’ actual medical records and create a single resource that is accessible 24 hours a day, seven days a week.
Representing an advanced, yet easy-to-use, approach to portable, electronic medical records management, MedeFile combines state-of-the-art technology and the Internet to make medical data instantly accessible to each MedeFile subscriber and his or her authorized healthcare providers from anywhere in the world. In addition to accessing one’s medical records through MedeFile’s secure Internet portal found at , members can carry their entire medical history and emergency information wherever they go on a unique device called a MedeDrive - a proprietary USB drive designed to be carried on a keychain. The MedeDrive plugs into any USB port of a Windows-based PC; and because MedeDrive automatically loads its own viewer, users do not require any special programs or software to view data. MedeMobile provides on-the-go subscribers with the ability to enjoy even greater flexibility and access to their personal health information wherever and whenever they need it.
For more information about MedeFile and the MedeFile system, visit .
Safe Harbor Statement Under the Private Securities Litigation Act of 1995
With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of MedeFile could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to respond to the evolving technological landscape, inability to finance the Company’s operations or expansion, inability to hire and retain qualified personnel, competitive pressure, changes in the general economic climate, including rising interest rates, and unanticipated events such as terrorist activities. In some cases, you can identify forward-looking statements by terminology such as “may,”"will,”"should,”"expect,”"plan,”"anticipate,”"believe,”"estimate,”"predict,”"potential” or “continue,” the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, and such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors associated with our Company, review our SEC filings.
FOR MORE MEDEFILE INFORMATION, PLEASE CONTACT:
Investors/Stockbrokers/Institutions/Media
Elite Financial Communications Group, LLC/Elite Media Group
Dodi Handy, President and CEO
407-585-1080 or via email at
MedeFile International, Inc.

MOUNT PROSPECT, Ill., June 27 /PRNewswire-USNewswire/ — Beginning in July 2008, the National Association of Boards of Pharmacy(R) (NABP(R)) will add a mid-level group to its categorization of Web sites selling prescription medicine. NABP will post on its Web site a list of Reviewed Internet Pharmacy Practice Sites, which, based on a review of the public information available for these sites, appear to comply with state and federal laws and NABP patient safety and pharmacy practice standards.
This new group will accompany the existing lists of “Recommended Internet Pharmacies” and “Not Recommended Sites,” posted on May 16, 2008, as part of the Internet Pharmacies section of the NABP Web site. NABP created the new section to serve as a resource, educating patients about buying medicine online, says NABP President Rich Palombo, RPh. “By posting this additional list of sites on the NABP Web site,” he says, “our goal is to provide a more complete picture of the Internet pharmacy landscape, so that patients who choose to buy prescription medicine over the Internet have ready access to the information they need to make informed choices.”
NABP advises patients to use these Reviewed Internet Pharmacy Practice Sites with caution, as information needed to conclusively determine the legitimacy and legality of these sites may not have been available. The Association asks patients to immediately report to NABP, via the online Report-a-Site feature, any activity indicating that the sites do not comply with state and federal laws or NABP criteria, for example, if the sites dispense medicine without a valid prescription or dispense non-FDA-approved medicine. NABP will continue to monitor the activity of these sites to determine continued inclusion on this list.
NABP continues to recommend that patients use sites accredited through the Verified Internet Pharmacy Practice Sites(TM) (VIPPS(R)) program. These “Recommended Internet Pharmacies,” representing more than 12,000 pharmacies nationwide, have undergone and successfully completed the rigorous NABP accreditation process, which includes a thorough review of all policies and procedures regarding the practice of pharmacy and dispensing of medicine over the Internet, as well as an on-site inspection of all facilities used by the site to receive, review, and dispense medicine.
NABP also continues to identify Internet drug outlets that appear to be out of compliance with state and federal laws or NABP patient safety and pharmacy practice standards and lists these sites as “not recommended” on its Web site. As of June 20, 2008, the list names 273 sites as “not recommended.” NABP has identified more than 300 additional suspiciously operating sites and is in the process of verifying these findings before posting them on the Web site.
Among the 273 Internet drug outlets currently listed as “not recommended,” violations of state and federal laws include 249 sites that do not require a valid prescription, 147 sites that offer foreign or non-FDA-approved drugs, and 102 sites that are located outside of the US and selling drugs illegally in the US. Moreover, many of these Internet drug outlets do not secure patients’ personal or financial information, placing them at risk of monetary loss and identity theft.
NABP is well positioned to provide information to patients about Internet drug outlets because of its unparalleled data banks regarding state licensure of pharmacies, pharmacists, technicians, and wholesale distributors, and its experience in the regulation of pharmacy practice. A trusted advocate for patient safety since 1904, NABP is dedicated to assisting the state boards of pharmacy in the regulation of pharmacy with the goal of protecting the health of patients and their families.
The lists of NABP-recommended, reviewed, and not recommended sites, along with program criteria and related patient information, are accessible in the Internet Pharmacies section of the NABP Web site, .
NABP is the independent, international, and impartial Association that assists its member boards and jurisdictions in developing, implementing, and enforcing uniform standards for the purpose of protecting the public health.
National Association of Boards of Pharmacy

NASHVILLE, Tenn., June 3 /PRNewswire/ — HealthLeaders-InterStudy, a leading provider of managed care market intelligence, reports that Illinois businesses and insurers are rethinking drug utilization as a component of healthcare costs by turning to value-based pharmacy design to lower costs. According to the latest Illinois health Plan Analysis, this idea has moved into Illinois with the work of insurers like health Alliance Medical Plans, which plans to expand its program to include new conditions.
Value-based pharmacy design (VBD) moves the costs of diagnosis and treatment for certain conditions, including drugs and supplies, down to the tier with the lowest copay or no copay at all if they are deemed to be essential to maintain health. The result is a formulary system that places some branded drugs to lower copay levels and generics to higher cost levels.
“In addition to health Alliance, look for other insurers to apply value- based pharmacy design in the state, particularly with their diabetes and cardiovascular patients,” states Roy Moore, market analyst for HealthLeaders- InterStudy and author of the report. “Results are defined as improvements in medication adherence, following the thought that by reducing a member’s copay, they are more likely to be adherent, which will lead to better outcomes and lower medical costs.”
Under several pilot programs, health Alliance has offered employers VBD as part of a broader health and wellness program involving workplace wellness and preventive medicine measures. On July 1, 2008, health Alliance is rolling out VBD to its fully insured risk group with a 10 percent coinsurance rate for diabetes drugs to its members, but no step therapy or prior authorization. The insurer is looking to expand the program to new conditions likes cardiovascular disease, osteoporosis and asthma.
About health Plan Analysis
Health Plan Analysis identifies key health plan trends, allowing healthcare businesses to create comprehensive strategic plans and sales strategies at state and local levels.
About HealthLeaders-InterStudy
HealthLeaders-InterStudy, a company of Decision Resources, Inc., is the authoritative source for managed care data and analysis. For more information, please visit .
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:

Elizabeth Marshall
Decision Resources, Inc.
781-296-2563

HealthLeaders-InterStudy

CHENGDU, China, May 12 /Xinhua-PRNewswire-FirstCall/ — Tianyin Pharmaceutical, Co., Inc., (BULLETIN BOARD: TYNP) , a manufacturer and supplier of modernized traditional Chinese medicine (”TCM”) based in Chengdu, China, today announced that the Company will present at Roth Third Annual China Discovery Tour on Tuesday, May 20, 2008 at 12:40 p.m. Beijing time. The Conference will be held at the Regent Hotel in Beijing, China.
Dr. Guoqing, Jiang, Tianyin’s Chairman and CEO, Mr. Allen Tang, assistant to the CEO, will be representing Tianyin Pharmaceutical at the conference and will be available for one-on-one meetings with analysts and investors throughout the day.
Management will discuss the Company’s current product portfolio, development pipeline, research and development platform, recent financial highlights and its long-term growth strategy.
Participation is by invitation and registration is mandatory. For more information on the conference contact your Roth representative or visit .
About Roth China Discovery Tour
The 3rd Annual China Discovery Tour will feature more than 70 companies in 7 cities throughout China, combining factory visits with management presentations in a mini conference format. This event is another chapter in Roth’s growing commitment to China. Over the past two years Roth has taken investors on more than 60 company visits in mainland China and hosted close to 200 China company presentations at its conferences. For more information about this invite only event, please contact .
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional Chinese medicine (”TCM”) in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 34 modernized TCMs in the market, 22 of which are listed in the highly selective National medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 51 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 523 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 869 employees. Tianyin achieved revenue of $20.4 million and net income of $3.95 million in FY2007 ending June 30, 2007.
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission.
For more information, please contact:

For the Company:
Allen Tang, Ph.D., MBA, Assistant to the CEO
Tel: 86-158-2122-5642 (China)
Email:

Investors:
HC International, Inc.
Alan Sheinwald
Tel: 1-914-669-0222 (US)
Email:
Tianyin Pharmaceutical, Co., Inc.

BALTIMORE, May 6 /PRNewswire/ — The Johns Hopkins Bloomberg School of Public Health and Wolters Kluwer Health, a division of Wolters Kluwer, today published the premiere issue of The Patient: Patient-Centered Outcomes Research, an international forum devoted to publishing research on patient-centered medicine.
The first academic journal in medicine to present solely the patient’s perspective, The Patient addresses the growing concern that modern medicine has failed to adequately satisfy the needs of its most important stakeholder, the patient. In an era of managed care and cost-containment, current trends in medicine are being driven primarily by the needs and wants of healthcare payors. Even in academic medicine, new therapies are often studied in terms of their risks and benefits, measures that are chosen by physicians and researchers, often without the involvement of patients. The new journal will publish research to help advance a medical environment where patients are not just subjects but part of the scientific process.
“Patients are important stakeholders in the science of medicine, yet their views often go unheard,” said John F.P. Bridges, Ph.D., founding Editor of The Patient and Assistant Professor, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health. “With The Patient, we set out to create a forum to present those views, not through anecdote or political means, but through hard science that presents patients’ views in a systematic and unbiased way.”
A leading expert on and proponent of patient-centered healthcare, Dr. Bridges oversees editorial direction for the new journal together with co-editor Christopher Carswell of Wolters Kluwer Health. Bryce McMurray, Product Director, Adis Journals, Wolters Kluwer Health, is in charge of marketing and circulation.
“We’re pleased to add The Patient to our longstanding family of Adis journals,” said McMurray. “We expect it will quickly become the torchbearer for patient-centric medicine and open a new window to all of the current, original research on the subject. In turn, we expect that it will spur further study.”
The inaugural issue includes contributions from world-renowned researchers investigating patient attitudes and preferences for healthcare, including topics such as health insurance; screening for disease; residential care; and the impact of ethnicity and gender on medication adherence. Also included is a profile of breast cancer survivor and patient advocate Lillie Shockney, Administrative Director of the Johns Hopkins Avon Foundation Breast Cancer Center and a leading researcher in the patient-centered outcomes area.
Published four times per year, The Patient is available globally by subscription in both print and electronic form by visiting . For those interested in sneaking a peak, the premier issue is available as a free download through July 31, 2008.
The Patient joins a long and trusted line of peer-reviewed Adis(TM) publications focused on improving patient health including Drugs, Drug Safety, and Pharmacoeconomics. The new journal is aimed at the international medical and health communities and serves researchers and scientists, and government, regulatory, insurance and pharmaceutical industry professionals including formulary managers; healthcare providers and policy makers; executives in managed care, health maintenance organizations and with healthcare payers; and executives in pharmaceutical companies and in pharmacoeconomic academics.
For more information about The Department of Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health, visit . For more about Wolters Kluwer Health, visit .
About Johns Hopkins Bloomberg School of Public Health
The Johns Hopkins Bloomberg School of Public Health (Baltimore) is dedicated to the education of a diverse group of research scientists and public health professionals, a process inseparably linked to the discovery and application of new knowledge, and through these activities, to the improvement of health and prevention of disease and disability around the world. For more, visit .
The Department of Health Policy and Management trains public health professionals and researchers in diverse disciplines and promotes the translation of public health science into practice and policy. Its mission is to train public health leaders to protect and improve the public’s health through effective, efficient and equitable policies, programs and services. The Department seeks to identify policies and interventions that promote and protect the health status of populations — strategies that improve access to health and preventive services, particularly among the most vulnerable methods that enhance the effectiveness and efficiency of health care for medical and mental illness, and models for improving the financing, organization and delivery of preventive and curative health services. For more, visit .
About Wolters Kluwer Health
Wolters Kluwer Health (Conshohocken, PA), a division of Wolters Kluwer, is a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry. Major brands include traditional publishers of medical and drug reference tools and textbooks, such as Lippincott Williams & Wilkins and Facts & Comparisons(R); electronic information providers, such as Ovid, Medi-Span(R) and ProVation(R); and pharmaceutical information providers such as Adis International and Source(R). Wolters Kluwer Health has annual revenues (2007) of $1,044 million (euro 761 million) and employs approximately 2,700 employees globally. For more information, visit .
Wolters Kluwer is a leading global information services and publishing company. The company provides products and services globally for professionals in the health, tax, accounting, corporate, financial services, legal, and regulatory sectors. Wolters Kluwer has annual revenues (2007) of euro 3.4 billion ($4.8 billion), maintains operations in over 33 countries across Europe, North America, and Asia Pacific and employs approximately 19,500 people worldwide. Wolters Kluwer is headquartered in Amsterdam, the Netherlands. Visit for information about our market positions, customers, brands, and organization.
Contact: Tom Kivett
Kivett & Company Communications
(212) 727-2935

Wolters Kluwer Health